NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.92 +0.20 (+0.52 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$38.92
Today's Range$38.56 - $39.1550
52-Week Range$35.10 - $46.80
Volume1.10 million shs
Average Volume2.54 million shs
Market Capitalization$10.57 billion
P/E Ratio19.17
Dividend YieldN/A
Beta0.87

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:HOLX
CUSIP43644010
Phone508-263-2900

Debt

Debt-to-Equity Ratio1.13
Current Ratio1.26
Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio19.17
Forward P/E Ratio17.45
P/E Growth1.82

Sales & Book Value

Annual Sales$3.06 billion
Price / Sales3.47
Cash Flow$3.6856 per share
Price / Cash10.56
Book Value$8.96 per share
Price / Book4.34

Profitability

EPS (Most Recent Fiscal Year)$2.03
Net Income$755.50 million
Net Margins-4.15%
Return on Equity20.86%
Return on Assets7.51%

Miscellaneous

Employees6,233
Outstanding Shares273,010,000

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) posted its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.53. The medical equipment provider had revenue of $789.30 million for the quarter, compared to analyst estimates of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.50 EPS. View Hologic's Earnings History.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

What price target have analysts set for HOLX?

14 Wall Street analysts have issued twelve-month price objectives for Hologic's stock. Their predictions range from $39.00 to $52.00. On average, they anticipate Hologic's stock price to reach $45.00 in the next twelve months. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:
  • 1. BTIG Research analysts commented, "in the New Year; Maintain Buy, $17 PT Our thesis is unchanged as SPNE put up solid results in 1Q18. Recall that SPNE has been transitioning the US spinal hardware business from legacy products to newer products that should (and are) growing at a faster pace, namely Mariner and Shoreline. While it has taken a few quarters, SPNE now has ~45% (up from ~24% in 1Q17) of its US spinal implant revenue coming from newer products. Combined with a growing exclusive distributor base, results came in slightly above expectations at $33.2M (+4.0%) relative to BTIG/Consensus of $32.5M/$32.7M respectively. In addition, orthobiologics continues to grow in the MSD from the strength of the portfolio, +5.2% WW, +4.9% US. SPNE is launching multiple products in both categories through FY18 (including a lateral system, Regatta, in 3Q18) while also developing instrumentation that works with navigation access. Collectively, the business continues its positive progression, the portfolio continues to build, and growth should increase to the MSD to HSD in 2H18. While macro spine dynamics remain soft, SPNE is a share taker (even if it is at a smaller scale than others). We maintain our Buy rating and $17 PT." (5/6/2018)
  • 2. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 5/1/18. The number of digital breast tomosynthesis (DBT) units increased by 199 during April which represents a 165.3% Y/ Y increase. DBT unit penetration increased to 31.8% from 31.1% last month and facility penetration increased to 49.6% from 48.1% last month. More importantly, DBT units placements are up 29.4% year-to-date (YTD) in 2018 vs. 2017. Assuming that HOLX is at least holding mammography market share, we believe its Breast Health business could accelerate some in 2018 given the strong YTD US mammography placements. We note that HOLX’s 3D mammography sales are less than 13% of its total sales." (5/1/2018)
  • 3. According to Zacks Investment Research, "Over the past three months, Hologic has been underperforming its industry. The company's  blood screening divestiture continues to impede growth. Foreign currency headwinds and a competitive landscape also continue to pose challenges for the company. On a positive note, Hologic has been witnessing strength in the Molecular Diagnostics. Moreover,  growth across all geographical regions buoys optimism. Buoyed on differentiated products, Breast Health has been performing well. We are upbeat about the recent CE Mark approval for Brevera breast biopsy system. Also, the PMA approval for the Aptima HBV Quant Assay for quantitation of hepatitis B viral load on the fully automated Panther system buoys optimism. Hologic’s strong cash position is encouraging." (4/30/2018)

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)
  • Mr. Robert W. McMahon, Chief Financial Officer (Age 49)
  • Mr. John M. Griffin, Gen. Counsel (Age 57)
  • Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)
  • Mr. Eric B. Compton, Consultant (Age 53)

Has Hologic been receiving favorable news coverage?

Media coverage about HOLX stock has trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hologic earned a news impact score of 0.13 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 46.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.33%), Victory Capital Management Inc. (2.00%), Wells Fargo & Company MN (1.76%), Northern Trust Corp (1.27%), Dimensional Fund Advisors LP (0.84%) and Guggenheim Capital LLC (0.64%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Which institutional investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, BlackRock Inc., Wells Fargo & Company MN, The Manufacturers Life Insurance Company , JPMorgan Chase & Co. and Thrivent Financial for Lutherans. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

Which institutional investors are buying Hologic stock?

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Natixis, Dimensional Fund Advisors LP, Stevens Capital Management LP, NS Partners Ltd, BNP Paribas Arbitrage SA, BB&T Securities LLC and Verition Fund Management LLC. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $38.92.

How big of a company is Hologic?

Hologic has a market capitalization of $10.57 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]


MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  600 (Vote Outperform)
Underperform Votes:  411 (Vote Underperform)
Total Votes:  1,011
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hologic (NASDAQ:HOLX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for Hologic in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 15.62%. The high price target for HOLX is $52.00 and the low price target for HOLX is $39.00. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.642.692.792.69
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.00$47.5385$48.3571$47.5385
Price Target Upside: 15.62% upside22.93% upside28.10% upside21.55% upside

Hologic (NASDAQ:HOLX) Consensus Price Target History

Price Target History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2018BTIG ResearchReiterated RatingBuy$44.00MediumView Rating Details
5/3/2018BarclaysLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00HighView Rating Details
5/3/2018Deutsche BankLower Price TargetHold ➝ Hold$44.00 ➝ $42.00HighView Rating Details
5/3/2018Stifel NicolausLower Price TargetHold ➝ Hold$42.00 ➝ $40.00HighView Rating Details
5/3/2018Leerink SwannDowngradeOutperform ➝ Market Perform$48.00 ➝ $41.00HighView Rating Details
5/3/2018Canaccord GenuityDowngradeBuy ➝ Hold$48.00 ➝ $39.00HighView Rating Details
5/1/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00 ➝ $43.00LowView Rating Details
4/17/2018Goldman Sachs GroupSet Price TargetBuy$43.00LowView Rating Details
2/9/2018Royal Bank of CanadaReiterated RatingHold$44.00HighView Rating Details
1/4/2018Bank of AmericaUpgradeNeutral ➝ Buy$50.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$50.00MediumView Rating Details
12/20/2017CowenUpgradeBuy$52.00LowView Rating Details
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/AView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$49.00 ➝ $44.00N/AView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $40.00N/AView Rating Details
7/17/2016UBSReiterated RatingBuy$45.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Hologic (NASDAQ:HOLX) Earnings History and Estimates Chart

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX) Earnings Estimates

2018 EPS Consensus Estimate: $2.19
2019 EPS Consensus Estimate: $2.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.49$0.52$0.50
Q2 20183$0.51$0.52$0.52
Q3 20184$0.55$0.57$0.57
Q4 20184$0.60$0.61$0.61
Q1 20192$0.61$0.63$0.62
Q2 20191$0.60$0.60$0.60
Q3 20192$0.61$0.65$0.63
Q4 20192$0.63$0.70$0.67

Hologic (NASDAQ HOLX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018Q2 2018$0.53$0.53$781.23 million$789.30 millionViewN/AView Earnings Details
2/8/2018Q1 2018$0.50$0.55$785.80 million$791.10 millionViewListenView Earnings Details
11/8/2017Q4 2017$0.49$0.50$792.54 million$802.90 millionViewN/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
11/8/2010Q4 2010$0.30$0.30ViewN/AView Earnings Details
8/2/2010Q3 2010$0.29$0.30ViewN/AView Earnings Details
5/3/2010Q2 2010$0.29$0.29ViewN/AView Earnings Details
2/1/2010Q1 2010$0.26$0.29ViewN/AView Earnings Details
11/9/2009Q4 2009$0.26$0.28ViewN/AView Earnings Details
8/3/2009Q3 2009$0.26$0.29ViewN/AView Earnings Details
5/4/2009Q2 2009$0.27$0.29ViewN/AView Earnings Details
2/2/2009Q1 2009$0.30$0.31ViewN/AView Earnings Details
11/11/2008Q4 2008$0.30$0.30ViewN/AView Earnings Details
7/30/2008Q3 2008$0.29$0.33ViewN/AView Earnings Details
5/1/2008Q2 2008$0.28$0.29ViewN/AView Earnings Details
1/31/2008Q1 2008$0.23$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Hologic (NASDAQ:HOLX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Hologic (NASDAQ HOLX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 99.80%
Insider Trading History for Hologic (NASDAQ:HOLX)
Insider Trading History for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ HOLX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2018Karleen Marie ObertonVPSell12,196$40.00$487,840.0013,825View SEC Filing  
3/16/2018Allison P. BeboSVPSell7,000$38.75$271,250.00View SEC Filing  
3/15/2018Charles J DockendorffDirectorBuy13,000$38.80$504,400.00View SEC Filing  
2/13/2018Namal NawanaDirectorBuy6,600$37.88$250,008.006,954View SEC Filing  
11/20/2017Karleen Marie ObertonVPSell1,023$39.84$40,756.32View SEC Filing  
11/13/2017Elaine UllianDirectorSell9,282$40.50$375,921.00View SEC Filing  
11/8/2017Karleen Marie ObertonVPSell1,256$39.29$49,348.249,406View SEC Filing  
11/6/2017Karleen Marie ObertonVPSell538$39.40$21,197.208,343View SEC Filing  
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.2423,810View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.7223,810View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.4045,634View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.6223,810View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.2020,994View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.4946,206View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.8043,165View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.5840,577View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.0038,832View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.0437,377View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00157,305View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.6425,839View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.6524,596View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.6023,810View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00152,305View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.4236,798View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.3613,260View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.0510,859View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.889,065View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.669,839View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.6842,898View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.0017,005View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.0067,140View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.8455,053View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.5423,257View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.269,023View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.6031,157View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.808,819View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.5020,983View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.003,914View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.003,914View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.0039,215View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.2039,215View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.8039,215View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.321,500View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00815,306View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00815,306View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.6811,341View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00122View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00815,306View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.0314,470View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00237,500View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00198,900View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.9011,341View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00825,891View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.0019,090View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.4027,749View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00825,891View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.005,052View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.2820,632View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Hologic (NASDAQ HOLX) News Headlines

Source:
DateHeadline
$800.84 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter$800.84 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - May 25 at 5:59 AM
$0.56 EPS Expected for Hologic, Inc. (HOLX) This Quarter$0.56 EPS Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - May 23 at 1:14 AM
Hologic, Inc. (HOLX) Receives Average Rating of "Hold" from AnalystsHologic, Inc. (HOLX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 21 at 7:52 AM
See what the IHS Markit Score report has to say about Hologic Inc.See what the IHS Markit Score report has to say about Hologic Inc.
finance.yahoo.com - May 9 at 5:05 PM
Hologic (HOLX) to Post Q4 2018 Earnings of $0.60 Per Share, Leerink Swann ForecastsHologic (HOLX) to Post Q4 2018 Earnings of $0.60 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 7 at 4:20 AM
Jefferies Group Weighs in on Hologics FY2018 Earnings (HOLX)Jefferies Group Weighs in on Hologic's FY2018 Earnings (HOLX)
www.americanbankingnews.com - May 7 at 3:58 AM
Hologic (HOLX) Expected to Earn Q3 2018 Earnings of $0.55 Per ShareHologic (HOLX) Expected to Earn Q3 2018 Earnings of $0.55 Per Share
www.americanbankingnews.com - May 7 at 3:10 AM
BTIG Research Reiterates "Buy" Rating for Hologic (HOLX)BTIG Research Reiterates "Buy" Rating for Hologic (HOLX)
www.americanbankingnews.com - May 6 at 10:34 AM
$0.57 EPS Expected for Hologic (HOLX) This Quarter$0.57 EPS Expected for Hologic (HOLX) This Quarter
www.americanbankingnews.com - May 5 at 3:11 PM
Hologic (HOLX) Cut to C- at TheStreetHologic (HOLX) Cut to C- at TheStreet
www.americanbankingnews.com - May 4 at 11:27 PM
Karleen Marie Oberton Sells 12,196 Shares of Hologic (HOLX) StockKarleen Marie Oberton Sells 12,196 Shares of Hologic (HOLX) Stock
www.americanbankingnews.com - May 4 at 7:52 PM
US STOCKS ON THE MOVE-Cardinal Health, Tesla, AIG, Spotify, Caterpillar, Hologic, KelloggUS STOCKS ON THE MOVE-Cardinal Health, Tesla, AIG, Spotify, Caterpillar, Hologic, Kellogg
www.nasdaq.com - May 4 at 8:47 AM
William Blair Analysts Decrease Earnings Estimates for Hologic (HOLX)William Blair Analysts Decrease Earnings Estimates for Hologic (HOLX)
www.americanbankingnews.com - May 4 at 8:41 AM
Jefferies Group Equities Analysts Increase Earnings Estimates for Hologic (HOLX)Jefferies Group Equities Analysts Increase Earnings Estimates for Hologic (HOLX)
www.americanbankingnews.com - May 4 at 8:37 AM
Research Analysts Offer Predictions for Hologics Q3 2018 Earnings (HOLX)Research Analysts Offer Predictions for Hologic's Q3 2018 Earnings (HOLX)
www.americanbankingnews.com - May 4 at 7:42 AM
Critical Review: Check Cap (CHEK) & Hologic (HOLX)Critical Review: Check Cap (CHEK) & Hologic (HOLX)
www.americanbankingnews.com - May 4 at 1:20 AM
Hologic (HOLX) PT Lowered to $50.00 at BarclaysHologic (HOLX) PT Lowered to $50.00 at Barclays
www.americanbankingnews.com - May 4 at 12:17 AM
Hologic (HOLX) Downgraded to "Sell" at ValuEngineHologic (HOLX) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 3 at 11:10 PM
Hologic (HOLX) Price Target Cut to $42.00Hologic (HOLX) Price Target Cut to $42.00
www.americanbankingnews.com - May 3 at 11:02 PM
Stifel Nicolaus Cuts Hologic (HOLX) Price Target to $40.00Stifel Nicolaus Cuts Hologic (HOLX) Price Target to $40.00
www.americanbankingnews.com - May 3 at 8:35 PM
Hologic (HOLX) Releases Quarterly  Earnings Results, Meets EstimatesHologic (HOLX) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 3 at 5:26 PM
Top Analyst Upgrades and Downgrades: Andeavor, Discovery, Estee Lauder, Esperion Therapeutics, Hologic, Nvidia ...Top Analyst Upgrades and Downgrades: Andeavor, Discovery, Estee Lauder, Esperion Therapeutics, Hologic, Nvidia ...
247wallst.com - May 3 at 4:57 PM
Hologics (HOLX) Q2 Earnings Meet Estimates, Revenues TopHologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
www.nasdaq.com - May 3 at 4:57 PM
Hologic (HOLX) Downgraded to Hold at Canaccord GenuityHologic (HOLX) Downgraded to Hold at Canaccord Genuity
www.americanbankingnews.com - May 3 at 4:31 PM
Hologic (HOLX) Cut to "Market Perform" at Leerink SwannHologic (HOLX) Cut to "Market Perform" at Leerink Swann
www.americanbankingnews.com - May 3 at 4:31 PM
Hologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPSHologic (HOLX) Reports In-Line Q2 EPS; Lowers Rev Guidance, Maintains EPS
www.streetinsider.com - May 3 at 8:45 AM
BRIEF-Hologic Receives Health Canada Authorization To Market Sculpsure LaserBRIEF-Hologic Receives Health Canada Authorization To Market Sculpsure Laser
www.reuters.com - May 3 at 8:45 AM
Hologic (HOLX) Q2 2018 Results - Earnings Call TranscriptHologic (HOLX) Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:45 AM
Edited Transcript of HOLX earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of HOLX earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:44 AM
Hologic Receives Health Canada Authorization to Market SculpSure® Laser for Non-Invasive Body Contouring (Lipolysis) of the Back, Inner and Outer Thighs, and Under the ChinHologic Receives Health Canada Authorization to Market SculpSure® Laser for Non-Invasive Body Contouring (Lipolysis) of the Back, Inner and Outer Thighs, and Under the Chin
finance.yahoo.com - May 3 at 8:44 AM
Hologic (HOLX) Updates Q3 Earnings GuidanceHologic (HOLX) Updates Q3 Earnings Guidance
www.americanbankingnews.com - May 2 at 7:33 PM
Hologic (HOLX) Updates FY18 Earnings GuidanceHologic (HOLX) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 7:32 PM
BRIEF-Hologic Q2 GAAP Loss Per Share $2.46BRIEF-Hologic Q2 GAAP Loss Per Share $2.46
www.reuters.com - May 2 at 5:08 PM
Hologic Q2 18 Earnings Conference Call At 4:30 PM ETHologic Q2 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - May 2 at 5:08 PM
Hologic Announces Financial Results for Second Quarter of Fiscal 2018Hologic Announces Financial Results for Second Quarter of Fiscal 2018
finance.yahoo.com - May 2 at 5:08 PM
Hologic: Fiscal 2Q Earnings SnapshotHologic: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 2 at 5:08 PM
Hologic (HOLX) Receives "Buy" Rating from Needham & Company LLCHologic (HOLX) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - May 1 at 4:18 PM
Breast Cancer Screening Tests 2018: Global Market Growth, Trends, and Forecasts to 2023 - ResearchAndMarkets.comBreast Cancer Screening Tests 2018: Global Market Growth, Trends, and Forecasts to 2023 - ResearchAndMarkets.com
www.businesswire.com - May 1 at 8:53 AM
Hologic (HOLX) Scheduled to Post Earnings on TuesdayHologic (HOLX) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:44 AM
Hologic (HOLX) Stock Rating Lowered by Zacks Investment ResearchHologic (HOLX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 30 at 11:41 AM
Hologic (HOLX) Rating Increased to Hold at BidaskClubHologic (HOLX) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 27 at 12:13 PM
Leading Womens Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of ...Leading Women's Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of ...
www.prnewswire.com - April 27 at 9:10 AM
Leading Womens Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of Obstetricians and Gynecologists Annual Clinical and Scientific MeetingLeading Women's Health Company Hologic Features Its Innovative Suite of Products at 2018 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting
finance.yahoo.com - April 27 at 9:10 AM
Minerva Surgical Requests Immediate Retraction of Misleading Intl Journal of Womens Health Publication that Compares NovaSure to Minerva®, Sponsored by HologicMinerva Surgical Requests Immediate Retraction of Misleading Int'l Journal of Women's Health Publication that Compares NovaSure to Minerva®, Sponsored by Hologic
www.prnewswire.com - April 26 at 8:01 PM
Global Virtual Reality (VR) in Healthcare Market 2015-2018 & 2023 Featuring Brainlab, Medtronic, Hologic, GE ...Global Virtual Reality (VR) in Healthcare Market 2015-2018 & 2023 Featuring Brainlab, Medtronic, Hologic, GE ...
www.prnewswire.com - April 26 at 4:56 PM
Check Cap (CHEK) and Hologic (HOLX) Critical ComparisonCheck Cap (CHEK) and Hologic (HOLX) Critical Comparison
www.americanbankingnews.com - April 26 at 9:38 AM
Hologic (HOLX) Given Consensus Recommendation of "Buy" by BrokeragesHologic (HOLX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 26 at 8:52 AM
Contrasting Check Cap (CHEK) and Hologic (HOLX)Contrasting Check Cap (CHEK) and Hologic (HOLX)
www.americanbankingnews.com - April 25 at 9:26 PM
BRIEF-FDA Approval Of Thinprep Integrated Imager Expands Automated Imaging For Pap Testing To More LabsBRIEF-FDA Approval Of Thinprep Integrated Imager Expands Automated Imaging For Pap Testing To More Labs
www.reuters.com - April 25 at 8:48 AM
Hologic (HOLX) Announces FDA Approval of ThinPrepHologic (HOLX) Announces FDA Approval of ThinPrep
www.streetinsider.com - April 25 at 8:48 AM

SEC Filings

Hologic (NASDAQ:HOLX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Hologic (NASDAQ:HOLX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Hologic (NASDAQ HOLX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.